BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31709529)

  • 1. STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.
    Ryan N; Anderson K; Volpedo G; Hamza O; Varikuti S; Satoskar AR; Oghumu S
    Int J Cancer; 2020 Mar; 146(6):1717-1729. PubMed ID: 31709529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Black raspberry extract inhibits regulatory T-cell activity in a murine model of head and neck squamous cell carcinoma chemoprevention.
    Ryan NM; Lamenza FF; Upadhaya P; Pracha H; Springer A; Swingler M; Siddiqui A; Oghumu S
    Front Immunol; 2022; 13():932742. PubMed ID: 36016924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
    Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
    Front Immunol; 2019; 10():1206. PubMed ID: 31214178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice.
    Brand M; Laban S; Theodoraki MN; Doescher J; Hoffmann TK; Schuler PJ; Brunner C
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT1 is regulated by TRIM24 and promotes immunosuppression in head and neck squamous carcinoma cells, but enhances T cell antitumour immunity in the tumour microenvironment.
    Anderson K; Ryan N; Nedungadi D; Lamenza F; Swingler M; Siddiqui A; Satoskar A; Upadhaya P; Pietrzak M; Oghumu S
    Br J Cancer; 2022 Sep; 127(4):624-636. PubMed ID: 35595823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer.
    Han N; Zhou D; Ruan M; Yan M; Zhang C
    Oral Oncol; 2023 Oct; 145():106524. PubMed ID: 37482043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells.
    Hix LM; Karavitis J; Khan MW; Shi YH; Khazaie K; Zhang M
    J Biol Chem; 2013 Apr; 288(17):11676-88. PubMed ID: 23486482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck.
    Norouzian M; Mehdipour F; Ashraf MJ; Khademi B; Ghaderi A
    BMC Immunol; 2022 Nov; 23(1):56. PubMed ID: 36376825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.
    Chen WC; Lai CH; Chuang HC; Lin PY; Chen MF
    Head Neck; 2017 Feb; 39(2):347-355. PubMed ID: 27696591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
    Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
    Front Immunol; 2020; 11():550250. PubMed ID: 33193316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
    Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
    Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC.
    Anderson K; Ryan N; Volpedo G; Varikuti S; Satoskar AR; Oghumu S
    Front Immunol; 2019; 10():3095. PubMed ID: 32010142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
    Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
    Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT1 Is Required for Decreasing Accumulation of Granulocytic Cells via IL-17 during Initial Steps of Colitis-Associated Cancer.
    Delgado-Ramirez Y; Baltazar-Perez I; Martinez Y; Callejas BE; Medina-Andrade I; Olguín JE; Delgado-Buenrostro NL; Chirino YI; Terrazas LI; Leon-Cabrera S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.
    Liu JF; Ma SR; Mao L; Bu LL; Yu GT; Li YC; Huang CF; Deng WW; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Oncol; 2017 Feb; 11(2):235-247. PubMed ID: 28102051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.